BioNJ’s Public Policy Committee serves as an important sounding board for BioNJ’s public policy efforts. The committee is comprised of executive and policy leadership in New Jersey’s life sciences innovation sector, from CEOs to government relations personnel and others. The committee meets regularly to provide BioNJ with feedback on policy machinations in Trenton and beyond; while participating in monthly update calls with BioNJ staff. Committee members frequently hear from guest speakers, including legislators, administrative and regulatory leaders, and others in the life sciences community at committee meetings, events and receptions.

Committee Members:

AbbVie – Joseph Oros, Director, State Government Affairs
Acadia Pharmaceuticals, Inc. – Mike Mattoon Vice President, Government Affairs & Policy
Adiso Therapeutics – Scott Megaffin, CEO
Amicus Therapeutics, Inc. – Paul Howard, Ph.D., Senior Director, Public Policy
AzurRx Therapeutics – James Sapirstein, MBA, RPh, President & CEO
Bayesian Biotech
 – John Maki, CEO
BeiGene – Jen Branstetter, Director, U.S. Patient Advocacy & Public Affairs
BeiGene – Rebecca (Becca) Davison, Director, U.S. Public Policy
BeiGene – Kristin Dolinski, Director, US Regulatory Policy and Intelligence
BeiGene – John Halliwell, Senior Director, Head of U.S. Government Affairs & Policy
BioAegis Therapeutics – Susan Levinson, Chief Executive Officer
BioMarin Pharmaceutical Inc. – Jennifer Hitchon, Director, Government Affairs
Bristol Myers Squibb Company
 – Ethan Hasbrouck, MPA, State Government Affairs
Eli Lilly & Company – Timothy Lyden, Director, State Government and Business Affairs
Faegre Drinker Biddle & Reath LLP – Maureen Hardwick, Partner
Faegre Drinker Biddle & Reath LLP
– Nick Manetto, Principal
Ferring Pharmaceuticals, Inc. – Tim Clark, Director, State Government Affairs and Head of State Advocacy
Ferring Pharmaceuticals, Inc. – Tegan Gelfand, Director, Government Affairs, Federal & Head of Public Policy
Ferring Pharmaceuticals, Inc. – Tiffany Shackelford, Senior Manager, Advocacy, Public Policy, and Health Equity
Gamida Cell – Michele Korfin, RPh, MBA, MBA, Chief Operating Officer & Chief Commercial Officer
Genmab – Christine Zettlemoyer, Head of Global Compliance
Gilead – Sherri Giorgio, Director, State Government Affairs
GSK – Chris Bryce, Director, State Government Affairs, US Government Affairs and Public Policy
Greenwich Biosciences – Jan Burrus, Government Affairs Director
Horizon Therapeutics – Liz Pujolas, Director, State Government Affairs & Policy
J&J – Chris Guiton, JD, Senior Director, US State Government Affairs
Kyowa Kirin – Stephanie Kelly, Global Head Regulatory Intelligence and Policy
Kyowa Kirin
 – Lauren Walrath, Head of Public Affairs
Merck & Co., Inc. – Domenick Argento, Associate Director, Account Management, Government Affairs & Policy
Novartis Pharmaceuticals – John Hohenwarter, Associate Director, State Government Affairs
Novartis Pharmaceuticals – Daniel Vigil, Executive Director and Head, State Policy
Novo Nordisk – Kate Barry, Associate Director, State Government Affairs
OncoSTING – Ambaw Bellete, President
Organon – Loredana Cromarty, US State Policy and Government Affairs
 – Rebecca Mandell, Head of Federal Policy and Government Affairs
Otsuka America Pharmaceutical
 – Patrick Stone, Associate Director for State Government Affairs, Mid-Atlantic Region
Pfizer – Anna Maria Maritato, Senior Director, State Government RelationsPTC Therapeutics, Inc. – Theodore Piper, Associate Director, State Government Affairs
Recordati Rare Diseases – Owen Murray, Vice President, Technical Operations and Quality Assurance
Regeneron –
Valerie Volpe, Director, Public Policy & Government Affairs
Rigby Consulting, LLC
 – Kevin Rigby, JD, Principal
Sanofi – George Coutros, Director, State Government Affairs
Soligenix, Inc. – Dennis Ondrejik, Program Manager
Tactical Therapeutics, Inc. – Rashida Karmali, JD, PhD, MBA, CLP, CEO & President
Taiho Oncology, Inc. – Ryan Garofalo, Associate Director, Professional Association Engagement
Teva Pharmaceuticals – Sarah Kan, Sr. Director, State Government Affairs
Teva Pharmaceuticals – Matt Sheffield, Director, Government Payer Systems 
Translatum Medicus, Inc.
 – Paul Howes, MBA, Executive Vice President
Vertex Pharmaceuticals – Martha Auster, Regional Director, Government Affairs
WuXi Biologics – Elizabeth Steele, Director, Public and Government Relations

BioNJ Committee Policy
Each BioNJ Committee has two Co-Committee Chairpersons, as identified and selected by BioNJ leadership and the working Committee. Each Committee Chairperson is elected for a two-year term. At BioNJ’s discretion, one Chairperson will transition off annually to allow for continuity of leadership.